Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Reports Positive Data from Phase II Trials of nAMD Therapy

publication date: Mar 19, 2024

Innovent Biologics (HK: 01801) reported that efdamrofusp alfa high-dose met its primary endpoint in the second Phase II trial that enrolled China patients with neovascular age-related macular degeneration (nAMD). The two Phase II studies, which compared the Innovent drug with Aflibercept, showed that IBI302 can be administered every 12 weeks. Innovent says the therapeutic properties of efdamrofusp alfa derive from its double targets: the VEGF domain that blocks angiogenesis, and the complement binding domain that inhibits an inflammatory response. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here